AR038197A1 - ACIDS 3- (IMIDAZOLIL) -2-ALCOXIPROPANOICS, PROCEDURES FOR THE PREPARATION OF THE SAME, PHARMACEUTICAL COMPOSITIONS OF THE SAME AND USE OF THE SAME IN THE PREPARATION OF MEDICINES - Google Patents

ACIDS 3- (IMIDAZOLIL) -2-ALCOXIPROPANOICS, PROCEDURES FOR THE PREPARATION OF THE SAME, PHARMACEUTICAL COMPOSITIONS OF THE SAME AND USE OF THE SAME IN THE PREPARATION OF MEDICINES

Info

Publication number
AR038197A1
AR038197A1 ARP030100165A ARP030100165A AR038197A1 AR 038197 A1 AR038197 A1 AR 038197A1 AR P030100165 A ARP030100165 A AR P030100165A AR P030100165 A ARP030100165 A AR P030100165A AR 038197 A1 AR038197 A1 AR 038197A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
haloalkyl
halo
nr13r14
independently selected
Prior art date
Application number
ARP030100165A
Other languages
Spanish (es)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0201389A external-priority patent/GB0201389D0/en
Priority claimed from GB0202027A external-priority patent/GB0202027D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of AR038197A1 publication Critical patent/AR038197A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Un compuesto ácido 3-(imidazolil)-2-alcoxipropanoico de acuerdo con la fórmula (1), donde: n es 0, 1, 2 ó 3; R1 se selecciona entre; a) un grupo alquilo C1-6 de cadena lineal o ramificada opcionalmente sustituida: b) un grupo alquenilo C2-6 de cadena lineal o ramificada opcionalmente sustituida, c) un grupo alquinilo C2-6 de cadena lineal o ramificada opcionalmente sustituida, d) arilo, e) heterociclo aromático, f) heterociclo, y g) H; estando los sustituyentes opcionales en los grupos (a), (b) y (c) anteriores seleccionados entre: cicloalquilo C3-7, arilo, heterociclo aromático, heterociclo, OR10, NR10R11, S(O)pR10, OC(O)R11, CO2R10, CONR10R11, SO2NR10R11, halo y NHSO2R10 y siendo p 0, 1, ó 2; cada uno de R2, R3, R4, R6, R7 y R9 se selecciona independientemente entre H y alquilo C1-6 de cadena lineal o ramificada opcionalmente sustituida con OR10 o halo; cada uno de R5 y R8 se seleccionan independientemente entre H y alquilo C1-6 de cadena lineal o ramificada opcionalmente sustituida con OR10 o halo, o tomados conjuntamente son una cadena alquileno C2-6; cada uno de R10 y R11 se selecciona independientemente entre H y alquilo C1-6 de cadena lineal o ramificada; arilo es un grupo monocíclico aromático o carbocíclico policíclico condensado de 6-14 miembros opcionalmente sustituido con uno o más grupos seleccionados entre R12, halo, OR13, NR13R14, NR13CO2R12, CO2R13, NR13SO2R12, CN, haloalquilo, O(haloalquilo), SR13, S(O)R12, SO2R12, OC(O)R13,SO2NR13R14 y C(O)NR13R14, cicloalquilo C3-7, O(cicloalquilo C3-7), R15 y OR15, siendo R12 alquilo C1-6 de cadena lineal o ramificada, seleccionándose cada uno de R13 y R14 independientemente entre H y alquilo C1-6 de cadena lineal o ramificada, y siendo R15 fenilo opcionalmente sustituido con R12, OR13, halo o haloalquilo; heterociclo aromático es un anillo aromático de 5 a 7 miembros que contiene de 1 a 3 heteroátomos, seleccionándose cada uno independientemente entre O, S; y N, estando dicho anillo opcionalmente sustituido con uno o más grupos seleccionados entre OR13, NR13R14, CO2R13, NR13CO2R12, R12, halo, CN, haloalquilo, O(haloalquilo), SR13, S(O)R12, SO2R12, OC(O)R13, NR13SO2R12, SO2NR13R14 y C(O)NR13R14,y heterociclo es un anillo de 3 a 8 miembros que contiene de 1 a 3 heteroátomos, cada uno seleccionado independientemente entre O, S, y N, estando dicho anillo saturado o parcialmente saturado, estando además dicho anillo opcionalmente sustituido con uno o más grupos seleccionados entre OR13, NR13R14, CO2R13,NR13CO2R14, R12, halo, CN, haloalquilo, O(haloalquilo), SR13, S(O)R12, SO2R12, OC(O)R13, NR13SO2R12, SO2NR13R14 y C(O)NR13R14, o un tautómero del mismo o una sal farmacéuticamente aceptable de dicho compuesto o de dicho tautómero. Procedimientos para la preparación de los mismos, composiciones farmacéuticas que los contienen, y uso de los mismos en la preparación de medicamentos útiles para tratar trastornos cardiovasculares.A 3- (imidazolyl) -2-alkoxypropanoic acid compound according to formula (1), where: n is 0, 1, 2 or 3; R1 is selected from; a) an optionally substituted linear or branched C1-6 alkyl chain group: b) an optionally substituted linear or branched C2-6 alkenyl group, c) an optionally substituted linear or branched C2-6 alkynyl group, d) aryl, e) aromatic heterocycle, f) heterocycle, and g) H; the optional substituents being in groups (a), (b) and (c) above selected from: C3-7 cycloalkyl, aryl, aromatic heterocycle, heterocycle, OR10, NR10R11, S (O) pR10, OC (O) R11, CO2R10, CONR10R11, SO2NR10R11, halo and NHSO2R10 and being p 0, 1, or 2; each of R2, R3, R4, R6, R7 and R9 is independently selected from H and C1-6 straight or branched chain alkyl optionally substituted with OR10 or halo; each of R5 and R8 are independently selected from H and C1-6 straight or branched chain alkyl optionally substituted with OR10 or halo, or taken together are a C2-6 alkylene chain; each of R10 and R11 is independently selected from H and C1-6 straight or branched chain alkyl; aryl is a 6-14 membered polycyclic aromatic monocyclic or carbocyclic mono group optionally substituted with one or more groups selected from R12, halo, OR13, NR13R14, NR13CO2R12, CO2R13, NR13SO2R12, CN, haloalkyl, O (haloalkyl), SR13, S (O) R12, SO2R12, OC (O) R13, SO2NR13R14 and C (O) NR13R14, C3-7 cycloalkyl, O (C3-7 cycloalkyl), R15 and OR15, R12 being C1-6 straight or branched chain alkyl, each of R13 and R14 being independently selected from H and C1-6 straight or branched chain alkyl, and R15 being phenyl optionally substituted with R12, OR13, halo or haloalkyl; aromatic heterocycle is a 5- to 7-membered aromatic ring containing 1 to 3 heteroatoms, each independently selected from O, S; and N, said ring being optionally substituted with one or more groups selected from OR13, NR13R14, CO2R13, NR13CO2R12, R12, halo, CN, haloalkyl, O (haloalkyl), SR13, S (O) R12, SO2R12, OC (O) R13, NR13SO2R12, SO2NR13R14 and C (O) NR13R14, and heterocycle is a 3 to 8 member ring containing 1 to 3 heteroatoms, each independently selected from O, S, and N, said ring being saturated or partially saturated, said ring being further optionally substituted with one or more groups selected from OR13, NR13R14, CO2R13, NR13CO2R14, R12, halo, CN, haloalkyl, O (haloalkyl), SR13, S (O) R12, SO2R12, OC (O) R13, NR13SO2R12, SO2NR13R14 and C (O) NR13R14, or a tautomer thereof or a pharmaceutically acceptable salt of said compound or said tautomer. Procedures for the preparation thereof, pharmaceutical compositions containing them, and use thereof in the preparation of medicaments useful for treating cardiovascular disorders.

ARP030100165A 2002-01-22 2003-01-21 ACIDS 3- (IMIDAZOLIL) -2-ALCOXIPROPANOICS, PROCEDURES FOR THE PREPARATION OF THE SAME, PHARMACEUTICAL COMPOSITIONS OF THE SAME AND USE OF THE SAME IN THE PREPARATION OF MEDICINES AR038197A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0201389A GB0201389D0 (en) 2002-01-22 2002-01-22 3-(imidazolyl)-2-alkoxypropanoic acids
GB0202027A GB0202027D0 (en) 2002-01-29 2002-01-29 3-(imidazolyl)-2-alkoxypropanoic acids

Publications (1)

Publication Number Publication Date
AR038197A1 true AR038197A1 (en) 2005-01-05

Family

ID=27614792

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030100165A AR038197A1 (en) 2002-01-22 2003-01-21 ACIDS 3- (IMIDAZOLIL) -2-ALCOXIPROPANOICS, PROCEDURES FOR THE PREPARATION OF THE SAME, PHARMACEUTICAL COMPOSITIONS OF THE SAME AND USE OF THE SAME IN THE PREPARATION OF MEDICINES

Country Status (24)

Country Link
EP (1) EP1467731A1 (en)
JP (1) JP2005520811A (en)
KR (1) KR20040077775A (en)
CN (1) CN1620291A (en)
AP (1) AP2004003084A0 (en)
AR (1) AR038197A1 (en)
BR (1) BR0307016A (en)
CA (1) CA2472238A1 (en)
EA (1) EA200400716A1 (en)
EC (1) ECSP045200A (en)
HR (1) HRP20040659A2 (en)
IL (1) IL162677A0 (en)
IS (1) IS7310A (en)
MA (1) MA27167A1 (en)
MX (1) MXPA04006573A (en)
NO (1) NO20043457L (en)
OA (1) OA12756A (en)
PA (1) PA8563501A1 (en)
PE (1) PE20030929A1 (en)
PL (1) PL371487A1 (en)
TN (1) TNSN04121A1 (en)
TW (1) TW200302094A (en)
UY (1) UY27615A1 (en)
WO (1) WO2003061652A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005051384A1 (en) * 2003-11-25 2005-06-09 Pfizer Limited Stabilised pharmaceutical compositions
JP2008536923A (en) * 2005-04-18 2008-09-11 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト Use of TAFI inhibitors to enhance myocardial reperfusion and facilitate PCI
EP2361910A4 (en) 2008-10-29 2012-08-01 Taisho Pharmaceutical Co Ltd Compound having tafia inhibitory activity
US8987242B2 (en) 2008-12-05 2015-03-24 Merck Sharp & Dohme Corp. Morpholinone compounds as factor IXA inhibitors
US8642582B2 (en) 2008-12-05 2014-02-04 Merck Sharp & Dohme Corp. Morpholinone compounds as factor IXa inhibitors
LT2548871T (en) * 2010-03-18 2017-09-25 Daiichi Sankyo Company, Limited Cycloalkyl-substituted imidazole derivative
CN102884053B (en) * 2010-03-18 2016-03-02 第一三共株式会社 Cyclopropanecarboxylacid acid derivative
CA2914533A1 (en) 2013-06-10 2014-12-18 Sanofi Macrocyclic urea derivatives as inhibitors of tafia, their preparation and their use as pharmaceuticals
EP3437641A4 (en) 2016-03-29 2019-11-20 Daiichi Sankyo Company, Limited Inflammatory intestinal disease therapeutic agent
TWI802591B (en) 2017-09-14 2023-05-21 日商第一三共股份有限公司 Compound having ring structures

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9901572D0 (en) * 1999-05-03 1999-05-03 Astra Ab New compounds
SK1732003A3 (en) * 2000-08-17 2004-08-03 Pfizer Substituted imidazoles as TAFIa inhibitors

Also Published As

Publication number Publication date
IL162677A0 (en) 2005-11-20
UY27615A1 (en) 2003-08-29
CN1620291A (en) 2005-05-25
WO2003061652A8 (en) 2004-09-10
CA2472238A1 (en) 2003-07-31
JP2005520811A (en) 2005-07-14
MA27167A1 (en) 2005-01-03
OA12756A (en) 2006-07-03
MXPA04006573A (en) 2004-10-04
NO20043457L (en) 2004-08-19
WO2003061652A1 (en) 2003-07-31
ECSP045200A (en) 2004-08-27
IS7310A (en) 2004-06-14
HRP20040659A2 (en) 2004-10-31
TNSN04121A1 (en) 2006-06-01
KR20040077775A (en) 2004-09-06
PA8563501A1 (en) 2004-08-31
PL371487A1 (en) 2005-06-13
EA200400716A1 (en) 2004-12-30
EP1467731A1 (en) 2004-10-20
TW200302094A (en) 2003-08-01
AP2004003084A0 (en) 2004-09-30
BR0307016A (en) 2004-11-03
PE20030929A1 (en) 2003-11-05

Similar Documents

Publication Publication Date Title
AR032781A1 (en) ARILED AMIDAS OF FURAN- AND THIOPHENCHARBOXYL ACIDS, PHARMACEUTICAL COMPOSITIONS, ITS USE FOR THE PREPARATION OF MEDICINAL PRODUCT AS ALSO THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR016523A1 (en) INDOL COMPOUNDS AS ANTI-INFLAMMATORY / ANALGESIC AGENTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND TREATMENT PROCEDURE
EA200500018A1 (en) BENZONE-CONDENSED HETEROARILAMIDE TYENOPIRIDIN DERIVATIVES USED AS THERAPEUTIC AGENTS, PHARMACEUTICAL COMPOSITIONS, INCLUDING THEM, AND THEIR APPLICATION
CO5690588A2 (en) DERIVATIVES OF 4-TETRAZOLILO-4 PHENYLPIPERIDINE FOR PAIN TREATMENT
AR048934A1 (en) MORPHOLINS
AR033408A1 (en) BISARILO COMPOUNDS CONTAINING ORTO NITROGEN, ORTO-SUBSTITUTES, PROCEDURES FOR THE PREPARATION, ITS USE FOR THE PREPARATION OF A MEDICINAL PRODUCT AS ALSO PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
NO20053460L (en) New compounds with selective inhibitory effect at GSK3
AR045255A1 (en) DERIVATIVES OF 1,2 BENZODIAZOL
AR042658A1 (en) DERIVATIVES OF 1,5-DIARIL-PIRROL-3-CARBOXAMIDE AND ITS USE AS CANABINOID RECEIVER MODULATORS
AR038044A1 (en) COMPOUND DERIVED FROM PIRAZINA, PHARMACEUTICAL COMPOSITION, ITS USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT, PROCESS FOR PREPARATION AND INTERMEDIATE COMPOUND IN THIS PROCESS.
AR058546A1 (en) DERIVATIVES OF 2- ADAMANTILUREA AS SELECTIVE INHIBITORS OF 11 BETA - HSD1
MX9305379A (en) NEW AMINO ACID DERIVATIVES, PROCEDURE FOR THEIR PREPARATION AND PHARMACEUTICAL PREPARATION CONTAINING THEM.
MXPA02002720A (en) New alpha-amino acid sulphonyl compounds, a process for their preparation and pharmaceutical compositions comprising them.
AR036045A1 (en) AMIDAS OF ANTRANILIC ACIDS WITH SIDE CHAIN OF HETEROARILSULFONILO, ITS EMPLOYMENT FOR THE PREPARATION OF A MEDICINAL PRODUCT, AS WELL AS PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR012489A1 (en) CORTICOTROPIN RELEASE FACTOR THIOPHENOPYRIDINE ANTAGONISTS. PROCEDURE FOR ITS PREPARATION, THE USE OF THE SAME IN THE PREPARATION OF A MEDICINAL PRODUCT, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM, PROCEDURE FOR THE PREPARATION OF SUCH COMPOSITION, AN INTERMEDIATE COMPOUND AND
EA200900279A1 (en) ARYLSULPHONAMIDE WITH ANALGETIC EFFECT
AR038197A1 (en) ACIDS 3- (IMIDAZOLIL) -2-ALCOXIPROPANOICS, PROCEDURES FOR THE PREPARATION OF THE SAME, PHARMACEUTICAL COMPOSITIONS OF THE SAME AND USE OF THE SAME IN THE PREPARATION OF MEDICINES
UY25332A1 (en) INDOL 2,3-SUBSTITUTED COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS
AR044830A1 (en) DERIVATIVES OF 4,5 DIARIL -3-HETEROCICLILPIRAZIN- 2- ESTER
AR057525A1 (en) GSK3 SELECTIVE INHIBITING COMPOUNDS AND A PROCESS FOR PREPARATION
AR017256A1 (en) INDOL SUBSTITUTED COMPOUNDS, METHOD FOR SOLID PHASE SYNTHESIS OF THE SAME, COMBINATION SETS TO BE EMPLOYED IN THAT METHOD, USE OF COMPOUNDS TO PREPARE A MEDICINAL PRODUCT AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM
PE20011183A1 (en) METABOLITES AGONISTS / ANTAGONISTS OF ESTROGEN
PE20021018A1 (en) DERIVATIVES OF ß - CARBOLINE
AR029001A1 (en) DERIVATIVES OF BENCIL-3,4-METHYLENDIOXYCHINAMIC AND THE USE OF THEM FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
CO5540322A2 (en) NEW HETEROCICLIC DERIVATIVES THAT INCLUDE A RING OF TETRAHYDROISOQUINOLINE AND PHARMACEUTICAL USE OF THE SAME

Legal Events

Date Code Title Description
FB Suspension of granting procedure